Sanofi may be late to the pricing-pledge party, but it’s not stopping with 9.9% price-hike limits. Instead, it's promising to keep any price increases at…

Sanofi and Regeneron's eczema med Dupixent has stormed out of the launch gate, prompting analysts to hike their sales estimates for 2017 to as much as $…

Regeneron’s flagship med Eylea fell short of sales expectations in Q1, raising questions as Praluent idles and potential big-earner Dupixent makes its debut.

Years ago, teaching hospitals started raising hurdles to pharma reps. A few even barred salespeople at the door. They may have changed prescribing habits, too.

Amgen has thrown a hefty sales force and DTC ads at its Repatha launch—and now, it has some long-awaited outcomes data. But sales signs aren’t pointing in the…

AbbVie investors were relieved when the company announced first-quarter results that exceeded forecasts, driven largely by an increase in Humira sales.

Some closely watched new drugs grabbed the spotlight at the American Academy of Neurology meeting this week, and plenty of other therapies put up results worth…

Neurocrine is out with its price for Ingrezza—and it’s even higher than some industry watchers expected.

Investors were in the mood for good news from Eli Lilly—and they got a bit of it in its first-quarter earnings report, even as pipeline worries cast a cloud…

Launches